TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Intravenous Nutrition Development, Research Organization (INDRO) AB
Closing information (x1000 NOK)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
304
|
224
|
161 |
| Financial expenses |
0
|
3
|
0 |
| Earnings before taxes |
432
|
1
|
1 |
| EBITDA |
-127
|
3
|
1 |
| Total assets |
5,119
|
4,297
|
4,383 |
| Current assets |
624
|
100
|
56 |
| Current liabilities |
212
|
117
|
74 |
| Equity capital |
4,907
|
4,180
|
4,309 |
| - share capital |
203
|
189
|
195 |
| Employees (average) |
1
|
1
|
1 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
95.9%
|
97.3%
|
98.3% |
| Turnover per employee |
304
|
224
|
161 |
| Profit as a percentage of turnover |
142.1%
|
0.4%
|
0.6% |
| Return on assets (ROA) |
8.4%
|
0.1%
|
0.0% |
| Current ratio |
294.3%
|
85.5%
|
75.7% |
| Return on equity (ROE) |
8.8%
|
0.0%
|
0.0% |
| Change turnover |
64
|
68
|
42 |
| Change turnover % |
27%
|
44%
|
35% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.